(177)Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial

(177)Lu-PSMA-617 is an effective therapy for metastatic castration-resistant prostate cancer (mCRPC). However, treatment resistance occurs frequently, and combination therapies may improve outcomes. We report the final safety and efficacy results of a phase I/II study combining (177)Lu-PSMA-617 with...

Descripción completa

Detalles Bibliográficos
Autores principales: Pathmanandavel, Sarennya, Crumbaker, Megan, Yam, Andrew O., Nguyen, Andrew, Rofe, Christopher, Hovey, Elizabeth, Gedye, Craig, Kwan, Edmond M., Hauser, Christine, Azad, Arun A., Eu, Peter, Martin, Andrew J., Joshua, Anthony M., Emmett, Louise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2022
Materias:
Featured Article of the Month
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973290/
https://www.ncbi.nlm.nih.gov/pubmed/34326127
http://dx.doi.org/10.2967/jnumed.121.262552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973290/
https://www.ncbi.nlm.nih.gov/pubmed/34326127
http://dx.doi.org/10.2967/jnumed.121.262552

Ejemplares similares